GlassScriptPhysician profile
Joel Braverman
NPI 1659488070
$842.66
in general payments reported to CMS, 2019-2025
10 companies · $209 in 2025
The $209 reported for 2025 was more than what 82% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.97 · 2020: $115 · 2022: $104 · 2023: $104 · 2024: $213 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $526.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $256.26 | 2023-2025 | Atricure Cryoice Cryoablation System (Cryo2), Synergy Ablation System, Atriclip Laa Exclusion System |
| Edwards Lifesciences Corporation | $180.57 | 2020-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Medtronic, INC. | $101.07 | 2025 | Micra, Linq II |
| Boston Scientific Corporation | $96.97 | 2019 | |
| Abiomed | $95.61 | 2024 | Impella |
| Cumberland Pharmaceuticals, INC. | $31.45 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $29.61 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.76 | 2025 | Lifevest |
| Chiesi USA, INC. | $15.75 | 2023 | Cleviprex |
| Pacira Pharmaceuticals Incorporated | $14.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Braverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.